- Home
- DFDV vs GOSS Comparison
DFDV vs GOSS Comparison
Compare DFDV & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFDV
- GOSS
- Stock Information
- Founded
- DFDV 2018
- GOSS 2015
- Country
- DFDV United States
- GOSS United States
- Employees
- DFDV N/A
- GOSS N/A
- Industry
- DFDV Finance: Consumer Services
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- DFDV Finance
- GOSS Health Care
- Exchange
- DFDV Nasdaq
- GOSS Nasdaq
- Market Cap
- DFDV 340.7M
- GOSS 347.8M
- IPO Year
- DFDV N/A
- GOSS 2019
- Fundamental
- Price
- DFDV $15.68
- GOSS $1.76
- Analyst Decision
- DFDV Buy
- GOSS Strong Buy
- Analyst Count
- DFDV 1
- GOSS 4
- Target Price
- DFDV $45.00
- GOSS $8.50
- AVG Volume (30 Days)
- DFDV 2.5M
- GOSS 3.5M
- Earning Date
- DFDV 08-12-2025
- GOSS 08-05-2025
- Dividend Yield
- DFDV N/A
- GOSS N/A
- EPS Growth
- DFDV N/A
- GOSS N/A
- EPS
- DFDV N/A
- GOSS N/A
- Revenue
- DFDV $1,975,695.00
- GOSS $40,237,000.00
- Revenue This Year
- DFDV $70.03
- GOSS N/A
- Revenue Next Year
- DFDV $142.86
- GOSS $63.97
- P/E Ratio
- DFDV N/A
- GOSS N/A
- Revenue Growth
- DFDV 1.47
- GOSS N/A
- 52 Week Low
- DFDV $0.48
- GOSS $0.66
- 52 Week High
- DFDV $53.88
- GOSS $2.23
- Technical
- Relative Strength Index (RSI)
- DFDV N/A
- GOSS 50.44
- Support Level
- DFDV N/A
- GOSS $1.91
- Resistance Level
- DFDV N/A
- GOSS $2.23
- Average True Range (ATR)
- DFDV 0.00
- GOSS 0.18
- MACD
- DFDV 0.00
- GOSS -0.03
- Stochastic Oscillator
- DFDV 0.00
- GOSS 16.81
About DFDV DeFi Development Corp. Common Stock
DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.